文献速递MDS 与骨髓增殖性肿瘤

骨髓增殖性肿瘤中的单细胞方法:旧问题,新技术

Single-cell methods in myeloproliferative neoplasms: old questions, new technologies.
PubMed 文献 · Blood · 2023-01-01

骨髓增殖性肿瘤(MPN)是由异常JAK/STAT信号驱动的克隆性干细胞来源造血恶性肿瘤,遗传简单但表型异质。本综述探讨单细胞方法如何为MPN生物学提供变革性见解,并讨论这些研究如何快速转化为临床路径并可能最终支撑精准医学。

要点

  • MPN遗传简单但表型异质,反映遗传与非遗传因素互作驱动的瘤内异质性。
  • 单细胞技术可解析细胞异质性,为预测临床病程和治疗提供新思路。
  • 多数MPN患者处于早期疾病阶段,仅小部分进展为侵袭性疾病,是癌症演化的可处理模型。

核心结论

  • 单细胞方法为MPN疾病生物学提供了变革性见解,这些见解广泛适用于人类癌症,并可能快速转化为临床路径、最终支撑精准医学。

研究设计与样本

  • 综述文章,探讨单细胞方法在骨髓增殖性肿瘤(MPN)中的应用。

主要发现

  • MPN是由异常Janus激酶-信号转导和转录激活蛋白(JAK/STAT)信号驱动的克隆性干细胞来源造血恶性肿瘤。
  • MPN遗传简单但表型异质,反映遗传与非遗传因素互作驱动的瘤内异质性。
  • MPN演化由使某些细胞亚群胜过其他亚群的因素决定。
  • 多数MPN患者处于早期疾病阶段,仅小部分进展为侵袭性疾病,是癌症演化的可处理模型。
  • 许多单细胞组学技术突破率先在MPN中得到应用。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Myeloproliferative neoplasms (MPN) are a group of clonal stem cell-derived hematopoietic malignancies driven by aberrant Janus kinase-signal transducer and activator of transcription proteins (JAK/STAT) signaling. Although these are genetically simple diseases, MPNs are phenotypically heterogeneous, reflecting underlying intratumoral heterogeneity driven by the interplay of genetic and nongenetic factors. Their evolution is determined by factors that enable certain cellular subsets to outcompete others. Therefore, techniques that resolve cellular heterogeneity at the single-cell level are ideally placed to provide new insights into MPN biology. With these insights comes the potential to uncover new approaches to predict the clinical course and treat these cancers, ultimately improving outcomes for patients. MPNs present a particularly tractable model of cancer evolution, because most patients present in an early disease phase and only a small proportion progress to aggressive disease. Therefore, it is not surprising that many groundbreaking technological advances in single-cell omics have been pioneered by their application in MPNs. In this review article, we explore how single-cell approaches have provided transformative insights into MPN disease biology, which are broadly applicable across human cancers, and discuss how these studies might be swiftly translated into clinical pathways and may eventually underpin precision medicine.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. O'Sullivan JM, Mead AJ, Psaila B, et al. Single-cell methods in myeloproliferative neoplasms: old questions, new technologies. Blood. 2023. PMID: 36322938. doi:10.1182/blood.2021014668

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。